Stock KALV KALVISTA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News KalVista Pharmaceuticals, Inc.

Equities

KALV

US4834971032

Real-time Estimate Cboe BZX
Other stock markets
 11:10:53 2024-04-25 am EDT 		5-day change 1st Jan Change
10.34 USD -0.05% Intraday chart for KalVista Pharmaceuticals, Inc. -10.00% -15.51%
Apr. 22 Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors CI
Apr. 15 Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
BU
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors
CI
Certain Common Stock of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
Certain performance stock options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
Certain restricted stock units of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
Certain Stock Options of KalVista Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 15-APR-2024.
CI
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
AQ
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
BU
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
BU
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
CI
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine Designation for Sebetralstat
AQ
KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
BU
KalVista Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024
CI
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
BU
KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
BU
KalVista Pharmaceuticals, Inc. to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
CI
KalVista Pharmaceuticals Names Benjamin Palleiko as CEO
MT
KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
BU
KalVista Pharmaceuticals, Inc. Announces Board Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KALV Stock
  4. News KalVista Pharmaceuticals, Inc.